Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bupropion for Smoking Cessation in Head and Neck Cancer
NCT02582008Phase 1Terminated
- Sponsor
- Wake Forest University Health Sciences
- Start
- Jan 2016
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bupropion in Tobacco Use Disorder (TUD), sponsored by Wake Forest University Health Sciences. Primary endpoint: Proportion of patients who are not smoking at 12 months. Started Jan 2016; status: terminated.
02
Drugs
bupropion
03
Conditions
Tobacco Use Disorder (TUD)
Beyond the preview
Go deeper on NCT02582008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02582008.